Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase.
Antithrombin (AT) is a serpin capable of trapping thrombin (IIa) in a stable and covalent complex. Complex formation is prevented by leukocyte elastase (LE) cleavage near the AT reactive centre. We mutated the known LE cleavage sites of AT to explore the possibility of producing an LE-resistant AT molecule. Initially, six rabbit AT variants differing only at residue 390 (P4) were generated in a cell-free system, and gel-based assays were used to assess IIa-mediated complex formation and LE-mediated cleavage of the variants. Substitution of charged residues (Glu or Arg) reduced complex formation by 50-60%, while the Ser variant was incapable of inhibiting thrombin; LE reactivity was less affected. The least (Trp) and most (Ser) affected variants were expressed in COS-1 cells. Again, the Ser variant was incapable of detectably reducing the rate of thrombin-mediated amidolysis while the Trp variant inhibited thrombin at a slightly reduced rate (-28%). LE inactivated the Trp variant and the wild-type AT to a similar extent. Recreation of the Trp mutation in COS-derived human AT showed similar results. Since retention of LE-sensitivity could have arisen due to cleavage at Val389 (P5), we produced and characterized a human AT substitution mutant with Trp at both P4 and P5. This variant showed a slight reduction in thrombin inhibitory activity (-22%), but remained susceptible to LE inactivation. These results suggest either that LE cleaves at secondary sites if its primary cleavage sites are blocked, or that the substrate specificity of LE differs in polypeptides as compared to peptide substrates.
Cunningham
M A
MA
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Blajchman
M A
MA
Sheffield
W P
WP
D019943:Amino Acid Substitution / Q000235:genetics / Q000502:physiology; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D000990:Antithrombin III / Q000235:genetics* / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics; D019556:COS Cells; D004347:Drug Interactions; D014644:Genetic Variation / Q000187:drug effects; D006801:Humans; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors* / Q000235:genetics*; D016297:Mutagenesis, Site-Directed / Q000235:genetics / Q000502:physiology; D011817:Rabbits; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D000990:Antithrombin III; D019272:Leukocyte Elastase; D013917:Thrombin